GILD


Gilead to Pay $1.25B to Glaxo to Settle Patent Infringement Lawsuit — Report

This article was originally published on TipRanks.com.

Gilead Slips 3.6% as Q4 Earnings Fall Year-Over-Year

This article was originally published on TipRanks.com Shares of Gilead Sciences, Inc.

Gilead Gets FDA Approval for Veklury

This article was originally published on TipRanks.com Gilead Sciences (NASDAQ: GILD) announced on Friday that it was granted expedited approval by the U.

FDA Puts Gilead’s Lenacapavir Injection on Clinical Hold

This article was originally published on TipRanks.com Gilead Sciences, Inc.

Understanding Gilead Sciences’ Newly Added Risk Factor

This article was originally published on TipRanks.com California-based Gilead Sciences (GILD) is a global biopharmaceutical company focused on developing treatments for cancers and …

Gilead Bags Marketing Authorization for Cancer Drug

Gilead Sciences, Inc. (GILD) revealed that it has been granted marketing authorization by the European Commission for Trodelvy, the company’s treatment drug for …

Gilead Submits Biologics License Application for Bulevirtide; Shares Rise

Shares of Gilead Sciences, Inc. (GILD) closed 1.

Gilead Slips 2.3% Despite Outstanding Q3 Results

Shares of California-based biopharmaceutical company Gilead Sciences, Inc. (GILD) slipped 2.

Gilead’s Yescarta Shows Significant Improvement in Survival in Follicular Lymphoma

Gilead Sciences’ (GILD) Kite Pharma reported follow-up data from the Zuma-5 trial of Yescarta in follicular lymphoma (FL). After a minimum period of …

Gilead’s Oral Epclusa Formulation Receives FDA Approval to Treat Hepatitis C in Children Aged 3 and Above

Gilead Sciences (GILD) has received approval from the U.S.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts